Connect with us

Anti-aging Stocks in the US

The global anti-aging market is worth billions of dollars with significant growth potential. Here’s a list of some of the anti-aging stocks looking to capitalize on that growth.
The post Anti-aging Stocks in the US appeared first on Investing News Ne…

Published

on

As the global population continues to get older, the popularity of anti-aging stocks is also rising thanks to advancements in technology and research on human longevity.

The desire to increase life quality and expectancy drives the top anti-aging stocks in the life science space as they pursue technologies and therapies aimed at slowing the aging process and preserving health.

According to Research and Markets, revenue from the global anti-aging market is projected to be worth a staggering US$64.04 billion by 2026, up from US$44.12 billion in 2020; it is seen growing at a compound annual growth rate of 6.1 percent during the forecast period, even with the impact of COVID-19.

 

Start Here:Investing in Genetics

   
Curious about this emerging market?Find out what new genetics investors need to know.
 

The research firm attributes this growth to new anti-aging treatments and products brought about by advancements in technology and increased investments in research and development, as well as higher demand for anti-aging products and devices from both young and older consumers.

Below is a brief overview of five anti-aging stocks on the NYSE and NASDAQ with market caps between US$50 million and US$500 million. All figures were current as of July 22, 2021.

1. Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Market cap: US$401.95 million; current share price: US$2.68

First on this list of anti-aging stocks, Lineage Cell Therapeutics works in the fields of regenerative medicine, human embryonic stem cell technology and induced pluripotent stem cell technology. It develops therapies that are based on stem cell biology and are intended to rebuild cell and tissue function lost due to degenerative diseases and injury.

In the company’s stem cell programs are: OpRegen, which is a cell replacement therapy in a Phase 2a clinical trial to treat advanced dry age-related macular degeneration; OPC1, which has completed Phase 2a clinical trials and is now in the planning phases for Phase 2b/3 trials for acute spinal cord injuries; and VAC2, which is in a Phase 1 clinical trial in patients with non-small-cell lung cancer.

2. Frequency Therapeutics (NASDAQ:FREQ)

Market cap: US$269.65 million; current share price: US$7.88

Frequency Therapeutics is a biotechnology company developing treatments related to hearing loss. Its lead product candidate is FX-322, and it hones in on sensorineural hearing loss. A number of Phase 1 to 2 trials are ongoing for various degrees of hearing loss, with topline results expected in H2 2021.

Looking further ahead, Frequency Therapeutics is also advancing preclinical research efforts aimed at repairing neurological damage in patients with multiple sclerosis.

3. Unity Biotechnology (NASDAQ:UBX)

Market cap: US$211.19 million; current share price: US$3.85

Unity Biotechnology’s mission statement revolves around prolonging the human lifespan. The company’s primary goal is to slow down or reverse age-related conditions and improve health. The lead product candidates in the company’s pipeline are UBX1325 and UBX1967, both of which are being tested as possible treatments for age-related diseases in the eye, such as age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy.

 

Start Here:Investing in Genetics

   
Curious about this emerging market?Find out what new genetics investors need to know.
 

UBX1325 is currently in Phase 2a trials, with data expected in the first half of 2022, while UBX1967 is undergoing pre-clinical trials. Unity’s pipeline also includes neurology programs aimed at neurodegenerative diseases and cognitive disorders.

4. CohBar (NASDAQ:CWBR)

Market cap: US$71.67 million; current share price: US$1.16

CohBar is taking a different approach to age-related disease through the research and development of mitochondria-based therapeutics, an emerging class of drugs. A novel group of peptides encoded within the mitochondrial genome has been shown to regulate metabolism and cell death.

These treatments have the potential to target diseases related to aging and metabolic dysfunction, such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular diseases and central nervous system conditions. The company expects to release data in Q3 2021 for its Phase 1a/1b clinical study of CB4211 for the potential treatment of nonalcoholic steatohepatitis and obesity.

5. AgeX Therapeutics (NYSEAMERICAN:AGE)

Market cap: US$58.04 million; current share price: US$1.53

Last on this list of anti-aging stocks is AgeX Therapeutics, a biotechnology company developing medical therapeutics related to human longevity. Its proprietary induced tissue regeneration longevity platform and PureStem technology are designed to aid in the development of medicines that address aging-related health concerns by harnessing the regenerative capacity of cells.

In early 2021, AgeX announced a research collaboration with Ohio State University. The company’s brown adipocyte tissue cell therapy candidate, called AgeX-BAT1, will be used in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity and metabolic health, including glucose metabolism and cardiac function.

This is an updated version of an article originally published by the Investing News Network in 2017.

Don’t forget to follow us @INN_LifeScience for real-time news updates.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

 

Start Here:Investing in Genetics

   
Curious about this emerging market?Find out what new genetics investors need to know.
 

The post Anti-aging Stocks in the US appeared first on Investing News Network.

Read More

Continue Reading

Uncategorized

February Employment Situation

By Paul Gomme and Peter Rupert The establishment data from the BLS showed a 275,000 increase in payroll employment for February, outpacing the 230,000…

Published

on

By Paul Gomme and Peter Rupert

The establishment data from the BLS showed a 275,000 increase in payroll employment for February, outpacing the 230,000 average over the previous 12 months. The payroll data for January and December were revised down by a total of 167,000. The private sector added 223,000 new jobs, the largest gain since May of last year.

Temporary help services employment continues a steep decline after a sharp post-pandemic rise.

Average hours of work increased from 34.2 to 34.3. The increase, along with the 223,000 private employment increase led to a hefty increase in total hours of 5.6% at an annualized rate, also the largest increase since May of last year.

The establishment report, once again, beat “expectations;” the WSJ survey of economists was 198,000. Other than the downward revisions, mentioned above, another bit of negative news was a smallish increase in wage growth, from $34.52 to $34.57.

The household survey shows that the labor force increased 150,000, a drop in employment of 184,000 and an increase in the number of unemployed persons of 334,000. The labor force participation rate held steady at 62.5, the employment to population ratio decreased from 60.2 to 60.1 and the unemployment rate increased from 3.66 to 3.86. Remember that the unemployment rate is the number of unemployed relative to the labor force (the number employed plus the number unemployed). Consequently, the unemployment rate can go up if the number of unemployed rises holding fixed the labor force, or if the labor force shrinks holding the number unemployed unchanged. An increase in the unemployment rate is not necessarily a bad thing: it may reflect a strong labor market drawing “marginally attached” individuals from outside the labor force. Indeed, there was a 96,000 decline in those workers.

Earlier in the week, the BLS announced JOLTS (Job Openings and Labor Turnover Survey) data for January. There isn’t much to report here as the job openings changed little at 8.9 million, the number of hires and total separations were little changed at 5.7 million and 5.3 million, respectively.

As has been the case for the last couple of years, the number of job openings remains higher than the number of unemployed persons.

Also earlier in the week the BLS announced that productivity increased 3.2% in the 4th quarter with output rising 3.5% and hours of work rising 0.3%.

The bottom line is that the labor market continues its surprisingly (to some) strong performance, once again proving stronger than many had expected. This strength makes it difficult to justify any interest rate cuts soon, particularly given the recent inflation spike.

Read More

Continue Reading

Spread & Containment

Another beloved brewery files Chapter 11 bankruptcy

The beer industry has been devastated by covid, changing tastes, and maybe fallout from the Bud Light scandal.

Published

on

Before the covid pandemic, craft beer was having a moment. Most cities had multiple breweries and taprooms with some having so many that people put together the brewery version of a pub crawl.

It was a period where beer snobbery ruled the day and it was not uncommon to hear bar patrons discuss the makeup of the beer the beer they were drinking. This boom period always seemed destined for failure, or at least a retraction as many markets seemed to have more craft breweries than they could support.

Related: Fast-food chain closes more stores after Chapter 11 bankruptcy

The pandemic, however, hastened that downfall. Many of these local and regional craft breweries counted on in-person sales to drive their business. 

And while many had local and regional distribution, selling through a third party comes with much lower margins. Direct sales drove their business and the pandemic forced many breweries to shut down their taprooms during the period where social distancing rules were in effect.

During those months the breweries still had rent and employees to pay while little money was coming in. That led to a number of popular beermakers including San Francisco's nationally-known Anchor Brewing as well as many regional favorites including Chicago’s Metropolitan Brewing, New Jersey’s Flying Fish, Denver’s Joyride Brewing, Tampa’s Zydeco Brew Werks, and Cleveland’s Terrestrial Brewing filing bankruptcy.

Some of these brands hope to survive, but others, including Anchor Brewing, fell into Chapter 7 liquidation. Now, another domino has fallen as a popular regional brewery has filed for Chapter 11 bankruptcy protection.

Overall beer sales have fallen.

Image source: Shutterstock

Covid is not the only reason for brewery bankruptcies

While covid deserves some of the blame for brewery failures, it's not the only reason why so many have filed for bankruptcy protection. Overall beer sales have fallen driven by younger people embracing non-alcoholic cocktails, and the rise in popularity of non-beer alcoholic offerings,

Beer sales have fallen to their lowest levels since 1999 and some industry analysts

"Sales declined by more than 5% in the first nine months of the year, dragged down not only by the backlash and boycotts against Anheuser-Busch-owned Bud Light but the changing habits of younger drinkers," according to data from Beer Marketer’s Insights published by the New York Post.

Bud Light parent Anheuser Busch InBev (BUD) faced massive boycotts after it partnered with transgender social media influencer Dylan Mulvaney. It was a very small partnership but it led to a right-wing backlash spurred on by Kid Rock, who posted a video on social media where he chastised the company before shooting up cases of Bud Light with an automatic weapon.

Another brewery files Chapter 11 bankruptcy

Gizmo Brew Works, which does business under the name Roth Brewing Company LLC, filed for Chapter 11 bankruptcy protection on March 8. In its filing, the company checked the box that indicates that its debts are less than $7.5 million and it chooses to proceed under Subchapter V of Chapter 11. 

"Both small business and subchapter V cases are treated differently than a traditional chapter 11 case primarily due to accelerated deadlines and the speed with which the plan is confirmed," USCourts.gov explained. 

Roth Brewing/Gizmo Brew Works shared that it has 50-99 creditors and assets $100,000 and $500,000. The filing noted that the company does expect to have funds available for unsecured creditors. 

The popular brewery operates three taprooms and sells its beer to go at those locations.

"Join us at Gizmo Brew Works Craft Brewery and Taprooms located in Raleigh, Durham, and Chapel Hill, North Carolina. Find us for entertainment, live music, food trucks, beer specials, and most importantly, great-tasting craft beer by Gizmo Brew Works," the company shared on its website.

The company estimates that it has between $1 and $10 million in liabilities (a broad range as the bankruptcy form does not provide a space to be more specific).

Gizmo Brew Works/Roth Brewing did not share a reorganization or funding plan in its bankruptcy filing. An email request for comment sent through the company's contact page was not immediately returned.

 

Read More

Continue Reading

Government

Walmart joins Costco in sharing key pricing news

The massive retailers have both shared information that some retailers keep very close to the vest.

Published

on

As we head toward a presidential election, the presumed candidates for both parties will look for issues that rally undecided voters. 

The economy will be a key issue, with Democrats pointing to job creation and lowering prices while Republicans will cite the layoffs at Big Tech companies, high housing prices, and of course, sticky inflation.

The covid pandemic created a perfect storm for inflation and higher prices. It became harder to get many items because people getting sick slowed down, or even stopped, production at some factories.

Related: Popular mall retailer shuts down abruptly after bankruptcy filing

It was also a period where demand increased while shipping, trucking and delivery systems were all strained or thrown out of whack. The combination led to product shortages and higher prices.

You might have gone to the grocery store and not been able to buy your favorite paper towel brand or find toilet paper at all. That happened partly because of the supply chain and partly due to increased demand, but at the end of the day, it led to higher prices, which some consumers blamed on President Joe Biden's administration.

Biden, of course, was blamed for the price increases, but as inflation has dropped and grocery prices have fallen, few companies have been up front about it. That's probably not a political choice in most cases. Instead, some companies have chosen to lower prices more slowly than they raised them.

However, two major retailers, Walmart (WMT) and Costco, have been very honest about inflation. Walmart Chief Executive Doug McMillon's most recent comments validate what Biden's administration has been saying about the state of the economy. And they contrast with the economic picture being painted by Republicans who support their presumptive nominee, Donald Trump.

Walmart has seen inflation drop in many key areas.

Image source: Joe Raedle/Getty Images

Walmart sees lower prices

McMillon does not talk about lower prices to make a political statement. He's communicating with customers and potential customers through the analysts who cover the company's quarterly-earnings calls.

During Walmart's fiscal-fourth-quarter-earnings call, McMillon was clear that prices are going down.

"I'm excited about the omnichannel net promoter score trends the team is driving. Across countries, we continue to see a customer that's resilient but looking for value. As always, we're working hard to deliver that for them, including through our rollbacks on food pricing in Walmart U.S. Those were up significantly in Q4 versus last year, following a big increase in Q3," he said.

He was specific about where the chain has seen prices go down.

"Our general merchandise prices are lower than a year ago and even two years ago in some categories, which means our customers are finding value in areas like apparel and hard lines," he said. "In food, prices are lower than a year ago in places like eggs, apples, and deli snacks, but higher in other places like asparagus and blackberries."

McMillon said that in other areas prices were still up but have been falling.

"Dry grocery and consumables categories like paper goods and cleaning supplies are up mid-single digits versus last year and high teens versus two years ago. Private-brand penetration is up in many of the countries where we operate, including the United States," he said.

Costco sees almost no inflation impact

McMillon avoided the word inflation in his comments. Costco  (COST)  Chief Financial Officer Richard Galanti, who steps down on March 15, has been very transparent on the topic.

The CFO commented on inflation during his company's fiscal-first-quarter-earnings call.

"Most recently, in the last fourth-quarter discussion, we had estimated that year-over-year inflation was in the 1% to 2% range. Our estimate for the quarter just ended, that inflation was in the 0% to 1% range," he said.

Galanti made clear that inflation (and even deflation) varied by category.

"A bigger deflation in some big and bulky items like furniture sets due to lower freight costs year over year, as well as on things like domestics, bulky lower-priced items, again, where the freight cost is significant. Some deflationary items were as much as 20% to 30% and, again, mostly freight-related," he added.

Read More

Continue Reading

Trending